Submitted by: Submitted by renzo89
Views: 301
Words: 89613
Pages: 359
Category: Business and Industry
Date Submitted: 06/10/2013 11:18 AM
P ro g r e s s AgA i n s t A l z h e i m e r ’ s D i s e A s e
Eli lilly and Company 2012 annual REpoRt notiCE of 2013 annual mEEting pRoxy StatEmEnt
Putting the Pieces together
the lilly Promise
Our Mission Lilly makes medicines that help people live longer, healthier, more active lives. Our Values Integrity | Excellence | Respect for People We promise to operate our business with absolute integrity and earn the trust of all, set the highest standards for our performance and for the performance of our products, and demonstrate caring and respect for all those who share in our mission and are touched by our work. Our Vision We will make a significant contribution to humanity by improving global health in the 21st century. Starting with the work of our scientists, we will place improved outcomes for individual patients at the center of what we do. We will listen carefully to understand patient needs and work with health care partners to provide meaningful benefits for the people who depend on us. Our Strategy We will create value for all our stakeholders by accelerating the flow of innovative medicines that provide improved outcomes for individual patients.
In 2012, Eli Lilly and Company saw promising signs that we’re beginning to piece together the puzzle that is Alzheimer’s disease—a disease that has so far defied the best efforts of medical science. While most of the public attention was on Phase III trial results for solanezumab, our monoclonal antibody being studied as a potential therapy for patients with Alzheimer’s disease, we continued to advance a multifaceted effort. (Please see pages 6–9.) At the same time, we also began to complete the puzzle of how we navigate through the current “YZ” period of patent expirations and return to growth in the years that follow. In the year after our Zyprexa® patent expired in most major markets, we met our financial performance goals, and received encouraging data from late-stage clinical trials for...